Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique

Alcohol septal ablation for the treatment of hypertrophic cardiomyopathy has been the subject of great interest, and the number of procedures performed is increasing despite an absence of randomized trial data. Although straightforward in concept, alcohol septal ablation may be considerably more difficult in actual practice. To optimize the results and prevent complications, the anatomy of the septal arcade architecture must be understood and the anatomic relationship between the septal artery and the specific portion of the septum to be ablated must be carefully delineated. For the latter, during the procedure, an echocardiographic contrast medium injection into the septal artery of interest is essential. Selection of the volume and amount of alcohol to be injected varies depending on the size and distribution of the septal artery. Specific complications such as conduction defects, hemodynamic compromise, ventricular arrhythmias, and inadequate gradient reduction can be minimized by specific technical approaches. After ablation, protocols are needed for periprocedural guidelines because some complications may occur late during the next several days. For optimal results, patients need to be selected after catheter assessment and combined echocardiography and angiography, and ablation techniques need to be scientific and rigorous. © 2005 Wiley‐Liss, Inc.

[1]  S. Qiao,et al.  [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy]. , 2006, Zhonghua nei ke za zhi.

[2]  S. Nagueh,et al.  Predictors of Outcome After Alcohol Septal Ablation Therapy in Patients With Hypertrophic Obstructive Cardiomyopathy , 2004, Circulation.

[3]  T. Cheng,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center. , 2004, International journal of cardiology.

[4]  A. van Rossum,et al.  Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[5]  P. Boekstegers,et al.  Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. , 2004, Zeitschrift fur Kardiologie.

[6]  P. Seggewiss,et al.  Catheter-based therapy for hypertrophic obstructive cardiomyopathy , 2004, Zeitschrift für Kardiologie.

[7]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[8]  Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. , 2003, Journal of the American College of Cardiology.

[9]  J. Ross,et al.  Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. , 2003, The Canadian journal of cardiology.

[10]  W. Spencer,et al.  Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: Short‐term results in 50 consecutive procedures , 2003, Clinical Cardiology.

[11]  J. Veselka,et al.  Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. , 2003, International journal of cardiology.

[12]  D. Fassbender,et al.  [Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy]. , 2003, Zeitschrift fur Kardiologie.

[13]  U. Gleichmann,et al.  Vorhersage des Risikos permanenter atrioventrikulärer Überleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie , 2003, Zeitschrift für Kardiologie.

[14]  S. Ommen,et al.  Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[15]  J. Plana,et al.  Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. , 2001, The American journal of cardiology.

[16]  W. Edwards,et al.  Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. , 2001, Mayo Clinic proceedings.

[17]  S. Nagueh,et al.  Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[18]  L. Faber,et al.  Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  H. Kuhn [Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience]. , 2000, Zeitschrift fur Kardiologie.

[20]  H. Kuhn Fünf Jahre TASH (Transkoronare Ablation der Septum Hypertrophie), eine Bilanz , 2000, Zeitschrift für Kardiologie.

[21]  H. Seggewiss Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. , 2000, European heart journal.

[22]  L. Faber,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients , 2000, Heart.

[23]  M. Quiñones,et al.  Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[24]  U. Gleichmann,et al.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[25]  U. Gleichmann,et al.  Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. , 1999, The Thoracic and cardiovascular surgeon.

[26]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[27]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[28]  M. Verani,et al.  Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[29]  U. Sigwart Non-surgical myocardial ablation: for hypertrophic obstructive cardiomyopathy. , 1998, Cardiologia.

[30]  D. Fassbender,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. , 1998, Journal of the American College of Cardiology.

[31]  D. Harrington,et al.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. , 1997, Circulation.

[32]  A. Tajik,et al.  Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. , 1996, Circulation.

[33]  U. Sigwart Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[34]  J. Seward,et al.  Hypertrophic obstructive cardiomyopathy: ten- to 21-year follow-up after partial septal myectomy. , 1983, The American journal of cardiology.

[35]  W. Henry,et al.  Operative Treatment in Hypertrophic Subaortic Stenosis: Techniques, and the Results of Pre and Postoperative Assessments in 83 Patients , 1975, Circulation.

[36]  W. Weidman,et al.  Idiopathic hypertrophic subaortic stenosis. Long-term surgical follow-up. , 1978 .

[37]  J. Ross,et al.  Obstruction to left ventricular outflow. Current concepts of management and operative treatment. , 1968, Annals of internal medicine.